

Rosuvastatin Slows the Progression of Aortic Stenosis Caused by Hypertension Regardless of Its Lipid-Lowering Effects

GUSTAVO GIUNTA^{†, 1}, EDUARDO GUEVARA^{MTSAC, 2}, LEANDRO MARZIALI³, LEONARDO GÓMEZ ROSSO⁴, TOMÁS MEROÑOS⁵, ROBERTO FAVALORO^{MTSAC, 6}, FERNANDO BRITES⁴, LUIS CUNIBERTI⁷

Received: 01/20/2011

Accepted: 04/03/2011

Address for reprints:

Dr. Gustavo Giunta
Laboratorio de Lípidos y
Aterosclerosis
Universidad Favaloro
Solís 453 - Piso 4^o
(C1078AAI) CABA, Argentina
Phone number: 054 (011) 4378-1200
Fax number: 054 (011) 4378-1365
e-mail: ggiunta@ffavaloro.org

SUMMARY

Background

There is epidemiological evidence associating cardiovascular risk factors with aortic valve stenosis. The development of aortic valve stenosis has been recently demonstrated in a hypertensive animal model. We hypothesize that treatment with rosuvastatin modifies this transformation.

Objective

To evaluate the effect of rosuvastatin on the development of aortic valve stenosis.

Material and Methods

Hypertension was induced in 43 male NZ rabbits by a one-kidney, one-clip Goldblatt procedure. The animals were randomly assigned to 3 groups: HT (n=17) without treatment; HT+R (n=14) treated with rosuvastatin 2.5 mg/kg/day and HT+R+C (n=12) treated with rosuvastatin 2.5 mg/kg/day + cholesterol-enriched diet to keep baseline cholesterol levels. A control group (CG) underwent sham surgery (n=15). The characteristics of the aortic valve were measured by echocardiography at baseline, 3 and 6 months after inducing hypertension.

Results

After 6 months of follow-up, SBP and DBP presented greater increase in the group HT (49% and 40%, respectively; $p < 0.001$) compared to groups treated with rosuvastatin (SBP = 23% and 25%; DBP = 28% and 26%; $p < 0.001$ for HT+R and HT+R+C, respectively). Total cholesterol decreased by 45.7% ($p < 0.01$) only in HT+R group. The aortic valve became thickened in the HT group (0.50 ± 0.01 vs. 0.62 ± 0.02 mm; $p < 0.01$); there were no significant differences in HT+R and HT+R+C. Finally, the aortic valve area was reduced in HT (0.277 ± 0.024 vs. 0.208 ± 0.014 cm²; $p < 0.05$), had no differences in HT+R and HT+R+C, and presented a non-significant increase in CG (0.264 ± 0.022 vs. 0.32 ± 0.016 cm²; $p = 0.07$).

Conclusions

Rosuvastatin slows the progression of aortic valve stenosis caused by hypertension. This protection might be independent of the lipid-lowering effect of the drug.

REV ARGENT CARDIOL 2012;80:14-20.

Key words > Statins - Aortic Valve Stenosis - Hypertension - Dyslipemia - Pleiotropic Effects

Lipid and Atherosclerosis Laboratory, Fundación Universitaria Dr. René G. Favaloro. Unit Associated to the CONICET, Buenos Aires, Argentina
Hospital Universitario, Fundación Favaloro, Buenos Aires, Argentina

Department of Clinical Biochemistry, Institute of Pathophysiology and Clinical Biochemistry (INFIBIOC), School of Pharmacy and Biochemistry, UBA, CONICET; Buenos Aires, Argentina

Sources of funding: This study was supported by a grant from the National Agency for Scientific and Technological Promotion, Ministry of Science, Technology and Productive Innovation (PICTO - project 20774).

^{MTSAC} Full Member of the Argentine Society of Cardiology

[†] To apply as full member of the Argentine Society of Cardiology

¹ Cardiologist. Cardiology Outpatient Clinics Department, Hospital Universitario, Fundación Favaloro

² Chief of the Department of Echocardiography, Hospital Universitario, Fundación Favaloro

³ Biochemist. Lipid and Atherosclerosis Laboratory, Fundación Universitaria Dr. René G. Favaloro. CONICET Buenos Aires, Argentina

⁴ Ph. D, UBA. Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, Institute of Pathophysiology and Clinical Biochemistry (INFIBIOC), UBA. CONICET. Buenos Aires, Argentina

⁵ Biochemist. Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, Institute of Pathophysiology and Clinical Biochemistry (INFIBIOC), UBA. CONICET. Buenos Aires, Argentina

⁶ Chief of the Department of Cardiothoracic Surgery. Hospital Universitario, Fundación Favaloro

⁷ Ph. D, UBA. Fundación Universitaria Dr. René G. Favaloro. CONICET. Buenos Aires, Argentina

Abbreviations >

AVA	Aortic valve area	HT+R+C	Hypertension + Rosuvastatin + Cholesterol group
AS	Aortic stenosis	H	Hypertension
CG	Control group	oxLDL	Oxidized low-density lipoprotein
cGMP	Cyclic guanosine monophosphate	LOX-1	Lectin-like oxidized LDL receptor
HDL-C	High density lipoprotein-cholesterol	NO	Nitric oxide
HMG CoA	3-hydroxy-3-methylglutaryl-coenzyme A	SBP	Systolic blood pressure
HTG	Hypertension group	SOD	Superoxide dismutase
HT+R	Hypertension + Rosuvastatin group	LV	Left ventricle
DBP	Diastolic blood pressure		

BACKGROUND

Aortic stenosis (AS) is the most common acquired valvular heart disease in adults and is the second most common condition requiring cardiovascular surgery. (1, 2) Despite the high prevalence of AS, most of the pathophysiological mechanisms still remain unclear. Several atherosclerosis risk factors have been associated with the development and progression of AS: age, smoking habits, high cholesterol levels, low high density lipoprotein-cholesterol (HDL-C) levels, hypertension (HT), high lipoprotein (a) levels and diabetes. (3-10) In this sense, our group has demonstrated the development of AS in an experimental model of normocholesterolemic hypertension, showing a direct association between the development of AS with high blood pressure levels. (11) Subsequent studies have shown increased oxidative stress with greater superoxide dismutase (SOD) activity and expression, increased tissue nitrotyrosine and reduction in tissue cGMP. Plasma levels of oxidized low-density lipoprotein (oxLDL) also increase. (12) Previous histological studies have demonstrated that lipid and oxidized lipoprotein depositions in the leaflets occur early in the development and progression of AS. (13, 14) Probably increased oxidative stress and other atherosclerotic stimuli due to HT may be responsible for the development of the aortic valve disease.

HMG-CoA reductase inhibitors, also known as statins, are efficient lipid-lowering agents in preventing cardiovascular events. (15, 16) In addition, these drugs have antioxidant and anti-inflammatory properties independent of their lipid-lowering effects. (17) However, recent clinical trials evaluating the use of statins in AS have not demonstrated a significant benefit; therefore, the indication of these agents in AS is controversial. (18-20) These trials have been conducted on patients with different degrees of severity of the disease; thus, it is difficult to establish if these drugs play any role in the prevention of early valve damage.

The hypothesis of this study is that rosuvastatin might reduce the deleterious impact of HT on the aortic valve and that this protective effect would be independent of its lipid-lowering effect.

MATERIAL AND METHODS**Model of hypertension**

Hypertension was induced in 43 male New Zealand rabbits by a one-kidney, one-clip Goldblatt procedure. (21) Direct

blood pressure measurements were obtained once a week from all animals through catheterization of the central ear artery. Hypertension was defined as blood pressure levels two standard deviations higher than the average preoperative values during two consecutive weeks. Cutoff values were 114 mm Hg for systolic blood pressure (SBP) and 88 mm Hg for diastolic blood pressure (DBP). Hypertensive animals were randomly assigned to one of the following groups: HTG (n = 17), fed a regular diet; HT+R (n = 14), regular diet + rosuvastatin 2.5 mg/kg/day in the drinking water and HT+R+C (n = 12) regular diet + rosuvastatin 2.5 mg/kg/day in the drinking water + cholesterol-enriched diet to keep normal cholesterol levels. Cholesterol supplementation started with a concentration of 0.04% which was modified according to plasma cholesterol levels measured every two weeks in each animal. A control group (CG) underwent sham surgery (n = 15). Animals were treated according to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.

Echocardiography

Transthoracic echocardiography was performed by applying standard practice guidelines at baseline, 3 and 6 months. Animals were sedated with an intramuscular injection of ketamine (20 mg/kg) and xilazine (1 mg/kg). Ultrasound images were obtained with a 12-MHz phased-array probe connected to a Sonos 5500 ultrasound scanner (Philips Medical Imaging, Andover, Massachusetts). A parasternal short-axis view at the mid left ventricular (LV) level was used to measure the following parameters: LV end-systolic and end-diastolic dimensions, interventricular septum and LV posterior wall thickness. The LV mass was calculated using the modified Devereux formula. (22) Peak and mean flow velocities across the aortic valve were determined using continuous-wave Doppler echocardiography by systematically sampling the flow from different acoustic windows and averaging the values for four to five beats. The maximal instantaneous gradient across the aortic valve and the mean gradient were derived from aortic Doppler velocities by the Bernoulli equation. The aortic valve area (AVA) was measured by the continuity equation. (23) The investigator who measured the echocardiographic parameters was blind to the treatment allocation of each animal.

Statistical Analysis

Continuous variables are expressed as mean $\pm$ standard deviation. Student's t test was used to analyze the differences between SBP and DBP at baseline and at the moment of randomization. Intragroup changes between the parameters measured during the follow-up period were evaluated using one-way repeated measures analysis of variance (ANOVA). Levene test was used to confirm the homogeneity of variances and Mauchly's sphericity test to determine if the assumption of sphericity had been violated. Intergroup comparisons were done with one-way ANOVA. Intragroup and intergroup differences were individualized

using the post hoc Sidak and Student-Newman-Keuls tests, respectively. A p value < 0.05 was considered statistically significant.

RESULTS

Blood pressure and plasma cholesterol levels

Baseline SBP and DBP values were 101.3 ± 1 mm Hg and 78.6 ± 0.8 mm Hg, respectively, and increased significantly at the moment of randomization (127.4 ± 2.2 mm Hg; $p < 0.001$ and 96 ± 1.9 mm Hg; $p < 0.001$). After 6 months of follow-up, the highest increase in SBP and DBP was seen in the HTG compared to baseline values (49% and 40%, respectively; $p < 0.001$). Both parameters also showed a significant increase in the groups HT+R and HT+R+C (SBP 23% and 25%; DBP 28% and 26%, respectively; $p < 0.001$); however, this increase was lower compared to that of the HTG (Figures 1 and 2).

Figure 3 shows total cholesterol levels during follow-up. Baseline cholesterol level was 48.8 ± 2.3 mg/dl. In the HT+R group, cholesterol level decreased significantly 2 weeks after initiating treatment (38.3 ± 4 mg/dl; $p < 0.05$). The maximum lipid-lowering effect occurred at week 8 at remained stable, reaching a reduction of 45.7% ($p < 0.01$) in the group HT+R at the end of the study.

Echocardiographic evaluation of aortic valve stenosis progression

Table 1 shows the echocardiographic parameters studied. There was a nonsignificant increase in LV mass in groups HTG, HT+R and HT+R+C over the study period. The analysis of LV mass index (LVMI) was determined in each animal by body weight and revealed a significant increase only in the HTG during echocardiographic evaluation at 6 months.

Animals in CG, HT+R and HT+R+C groups did not show significant differences in leaflet thickness throughout the study, while those in the HTG had a progressive and significant increase (baseline: 0.50 ± 0.02 mm; 3 months: 0.58 ± 0.02 mm, $p < 0.05$ vs. baseline; 6 months: 0.62 ± 0.02 mm, $p < 0.005$ vs. baseline).

Finally, as shown in Figure 4, AVA showed a significant reduction in the HTG at 3 months (0.200 ± 0.029 cm²; $p < 0.05$) and 6 months (0.208 ± 0.014 cm²; $p < 0.05$) compared to baseline values (0.277 ± 0.024 cm²). Conversely, animals in HT+R and HT+R+C groups did not show significant differences in AVA during the study, while those in CG presented a significant increase at 6 months (baseline: 0.264 ± 0.022 vs. 6 months: 0.32 ± 0.016 cm²; $p = 0.07$). As shown in Table 1, peak aortic valve gradient increased significantly only in the HTG at 3 months (baseline: 9.8 ± 1.3 mm Hg vs. 3 months: 20.5 ± 3.6 mm Hg; $p < 0.05$) and at 6 months (21.2 ± 3.4 mm Hg; $p < 0.05$).

DISCUSSION

The prevalence of AVS is high, being the leading cause of acquired heart valvular disease in adults. (1,




Fig. 1. Systolic blood pressure during the study. (■) CG, (●) HT group, (◆) HT+R group and (▲) HT+R+C group. * $p < 0.001$ vs. CG; † $p < 0.05$ vs. HT-R; ‡ $p < 0.05$ vs. HT-R-C.




Fig. 2. Diastolic blood pressure during the study. (■) CG, (●) HT group, (◆) HT+R group and (▲) HT+R+C group. * $p < 0.001$ vs. CG.

2) Progression of AS is associated with morbidity and mortality, thus many patients undergo aortic valve replacement. (24) For this reason there is an increasing interest in elucidating the mechanisms related with the development and evolution of the disease and in finding the therapeutic tools to delay its progression. The main result of the present study is that treatment with rosuvastatin attenuated the development of AS in an experimental model of hypertension independently of changes in plasma cholesterol levels.




Fig. 3. Total cholesterol concentration by group during 6-month follow-up. (■) CG, (●) HT group, (◆) HT+R group and (▲) HT+R+C group. * $p < 0.001$ vs. GC.

For several years, AS was considered a passive degenerative process of the aortic valve; however, it has come to be recognized as an active process sharing many clinical and histological features with atherosclerosis. (13) In fact, several studies have demonstrated an association between conventional risk factors for atheromatosis and greater risk for the development and progression of AS. (3-10) The histological features of the disease include lipoprotein deposition, chronic inflammation and tissue remodeling. (13) A recent study has reported the presence of oxLDL in the leaflets of patients with AS and has shown a correlation between these oxidized lipids, inflammation and the degree of leaflet calcification. (25)

Of interest, a considerable proportion of patients with AS have normal plasma cholesterol levels, suggesting that other factors must be related with the development of the disease. (9, 19) The importance of HT in this process has been highlighted by few epidemiological studies. (26, 27) Based on the hypothesis that HT per se might produce AS, our group has previously demonstrated that induction of experimental chronic HT reduces the AVA, increases peak and mean aortic gradient and produces thickening of the aortic valve leaflets after 4 months of follow-up. (11) The oxidative profile associated with HT (12) showed: 1) reduction in the SOD activity, one of the main components of the antioxidant defense mechanism, 2) increased tissue nitrotyrosine, indirectly reflecting sequestration of nitric oxide (NO), 3) reduced cGMP, a secondary mediator of NO action, and, 4) increased plasma levels of oxLDL. Although these preclinical results occurred with normal cholesterol levels, the pathophysiological role of plasma lipid levels in this state of high oxidative stress should not be ruled out. In fact, HT increases infiltration of macromolecules, proteins and lipoproteins through the endothelial

barrier (28) increasing vascular sensitivity even with physiological levels of atherogenic plasma lipids. In consequence, we speculate about the possibility that plasma lipids are a risk factor for the development of AS, even within normal concentrations. Thus, it is interesting to evaluate the impact of a statin on the development of AS in HT and normal cholesterol levels. The present study shows that rosuvastatin reduces the progression of AS after 6 months of exposure to experimental HT, demonstrating that the drug attenuates AVA decrease while the control group presents a non-significant increase in the AVA attributed to animals' growth. Similar benefits are observed in leaflet thickening. These findings are present in both rosuvastatin groups; therefore, the protective effect achieved on the aortic valve might be different from the lipid-lowering effect.

Most pharmacological agents are designed for a specific action; however, in some cases it is possible to identify actions other than those for which the




Fig. 4. Outcomes of the aortic valve area by group during follow-up. (■) CG, (●) HT group, (◆) HT+R group and (▲) HT+R+C group. * $p < 0.001$ vs. CG.

Table 1. Preoperative variables

		Control	HTG	HT+R	HT+R+C
AVA (cm ²)	Baseline	0,264 ± 0,022	0,277 ± 0,024	0,259 ± 0,019	0,259 ± 0,021
	3 months	0,305 ± 0,015	0,2 ± 0,029 ^{††}	0,266 ± 0,022	0,249 ± 0,02
	6 months	0,322 ± 0,016	0,208 ± 0,014 ^{††}	0,262 ± 0,019	0,271 ± 0,021
LT (mm)	Baseline	0,48 ± 0,02	0,5 ± 0,02	0,5 ± 0,01	0,47 ± 0,01
	3 months	0,5 ± 0,02	0,58 ± 0,02 ^{††}	0,53 ± 0,02	0,52 ± 0,02
	6 months	0,49 ± 0,02	0,62 ± 0,02 ^{††}	0,48 ± 0,01	0,54 ± 0,02
Peak gradient (mm Hg)	Baseline	10,6 ± 1,1	9,8 ± 1,3	10,1 ± 1,3	9,3 ± 1,2
	3 months	9,6 ± 1,2	20,5 ± 3,6 ^{††}	13,5 ± 2,4	12,1 ± 2,9
	6 months	9,3 ± 1	21,2 ± 3,4 ^{††}	10,1 ± 1	13,7 ± 3,9
Mean gradient (mm Hg)	Baseline	5,8 ± 0,7	5,5 ± 1	5,8 ± 0,7	4,8 ± 1,2
	3 months	5,1 ± 0,6	10,6 ± 1,7 ^{††}	7,3 ± 1,3	6,4 ± 1,7
	6 months	5,1 ± 0,6	11 ± 1,7 ^{††}	5,4 ± 0,7	7 ± 1,8
LVDD (cm)	Baseline	1,27 ± 0,04	1,29 ± 0,05	1,28 ± 0,04	1,32 ± 0,04
	3 months	1,31 ± 0,05	1,24 ± 0,05	1,4 ± 0,07	1,3 ± 0,04
	6 months	1,34 ± 0,4	1,3 ± 0,07	1,31 ± 0,04	1,32 ± 0,04
LVSD (cm)	Baseline	0,85 ± 0,04	0,82 ± 0,03	0,86 ± 0,03	0,77 ± 0,04
	3 months	0,9 ± 0,04	0,77 ± 0,05	0,9 ± 0,07	0,85 ± 0,06
	6 months	0,9 ± 0,04	0,78 ± 0,04	0,87 ± 0,04	0,92 ± 0,04
IVS (cm)	Baseline	0,28 ± 0,01	0,29 ± 0,01	0,29 ± 0,01	0,29 ± 0,01
	3 months	0,29 ± 0,01	0,33 ± 0,01 ^{††}	0,33 ± 0,02 [†]	0,31 ± 0,02
	6 months	0,3 ± 0,01	0,34 ± 0,01 ^{††}	0,31 ± 0,01	0,31 ± 0,01
PW (cm)	Baseline	0,27 ± 0,01	0,29 ± 0,01	0,3 ± 0,01	0,28 ± 0,01
	3 months	0,28 ± 0,01	0,32 ± 0,02	0,32 ± 0,02	0,32 ± 0,02
	6 months	0,3 ± 0,01	0,34 ± 0,02	0,32 ± 0,01	0,33 ± 0,02
LVM (g)	Baseline	4,5 ± 0,2	4,4 ± 0,4	4,7 ± 0,4	4,7 ± 0,3
	3 months	4,6 ± 0,3	5,6 ± 0,6	5,7 ± 0,5	5,3 ± 0,3
	6 months	4,9 ± 0,3	6,2 ± 0,7	5,4 ± 0,3	5,4 ± 0,4
LVMI (g/kg)	Baseline	1,31 ± 0,05	1,31 ± 0,06	1,32 ± 0,05	1,31 ± 0,06
	3 months	1,33 ± 0,05	1,59 ± 0,11	1,41 ± 0,04	1,43 ± 0,05
	6 months	1,43 ± 0,03	1,78 ± 0,13 ^{††}	1,42 ± 0,06	1,36 ± 0,09

AVA: Aortic valve area. LVDD: Left ventricular diastolic dimension. LVSD: Left ventricular systolic dimension. LT: Leaflet thickness. IVS: Interventricular septum thickness. LW: Left wall thickness. LVM: Left ventricular mass. LVMI: Left ventricular mass index. One-way repeated measures analysis of variance (OWRMANOVA). * p < 0.05 vs. baseline in the same group; † p < 0.05 vs. control during the same time interval; ‡ p < 0.005 vs. baseline in the same group.

agent was specifically developed: these actions are called pleiotropic effects. (17, 29-31) Of importance, the groups treated with rosuvastatin had a significant reduction in blood pressure levels (16 mm Hg in SBP and 8 mm Hg in DBP) compared to HTG. Statins might exert some influence on blood pressure in vivo by several mechanisms: improving endothelial dysfunction, (32-36), reducing the inflammatory profile (29-31, 37) and modulating the renin-angiotensin-aldosterone system. (34, 38) Independently of the mechanism of action involved, the antihypertensive effect of rosuvastatin is not affected by cholesterol titration and may have probably contributed to the benefit observed on the aortic valve. Yet, the drug may have a direct action on valvular gene expression regulation that cannot be ruled out. In fact, Kang et al. reported that rosuvastatin reduces angiotensin II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1 (lectin-like oxidized LDL receptor), (39) a specific receptor for oxLDL, constituting an attractive molecular mechanism to explore in AS caused by hypertension.

CONCLUSIONS

The results of this study provide evidence about a potential benefit of statins in the protection of aortic valve damage caused by HT, particularly through pleiotropic effects. Future studies should evaluate the role of these effects on the clinical impact of statins in cardiovascular prevention.

RESUMEN

La rosuvastatina atenúa la progresión de la estenosis aórtica generada por hipertensión arterial, independientemente de sus efectos hipolipemiantes

Introducción

Existe evidencia epidemiológica que vincula factores de riesgo cardiovascular con la estenosis valvular aórtica. Recientemente se ha demostrado el desarrollo de estenosis valvular aórtica en un modelo de hipertensión arterial en animales. Planteamos la hipótesis de que el tratamiento con rosuvastatina modifica esta transformación.

Objetivo

Evaluar el efecto de la rosuvastatina sobre el desarrollo de estenosis valvular aórtica.

Material y métodos

Se instrumentaron conejos NZ machos ($n = 43$) con el modelo 1-riñón 1-clip de Goldblatt para generar hipertensión arterial. Los animales fueron aleatorizados a: HT ($n = 17$) que no recibió otro tratamiento, HT+R ($n = 14$) tratado con rosuvastatina 2,5 mg/kg/día y HT+R+C ($n = 12$) tratado con rosuvastatina 2,5 mg/kg/día + suplemento de colesterol dietético para mantener los niveles basales de colesterol plasmático. Un grupo control (GC) fue sometido a cirugía simulada ($n = 15$). Las características de la válvula aórtica se midieron por ecografía en condiciones basales y a los 3 y a los 6 meses de hipertensión arterial.

Resultados

A los 6 meses de seguimiento, los incrementos de PAS y PAD fueron más elevados en HT (49% y 40%, respectivamente; $p < 0,001$) en comparación con los grupos tratados con rosuvastatina (PAS = 23% y 25%; PAD = 28% y 26%; $p < 0,001$ para HT+R y HT+R+C, respectivamente). El colesterol total se redujo el 45,7% ($p < 0,01$) sólo en HT+R. El espesor valvar se incrementó en HT ($0,50 \pm 0,01$ vs. $0,62 \pm 0,02$ mm; $p < 0,01$), sin mostrar diferencias en HT+R y HT+R+C. Finalmente, el área valvular aórtica mostró una reducción en HT ($0,277 \pm 0,024$ vs. $0,208 \pm 0,014$ cm²; $p < 0,05$), sin cambios en HT+R y HT+R+C y un aumento no significativo en el GC ($0,264 \pm 0,022$ vs. $0,32 \pm 0,016$ cm²; $p = 0,07$).

Conclusión

La rosuvastatina atenúa la progresión de la estenosis valvular aórtica generada por hipertensión arterial. Esta protección podría ser mediada por efectos no hipolipemiantes de estas drogas.

Palabras clave > Estatinas - Estenosis de la válvula aórtica
Hipertensión - Dislipidemias - Efectos pleiotrópicos.

BIBLIOGRAPHY

- Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. *J Am Coll Cardiol* 1993;21:1220-5.
- Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet* 2006;368:1005-11.
- Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium and phosphorus, diabetes mellitus, aortic valve stenosis and history of systemic hypertension with presence or absence of mitral annular calcium in persons older than 62 years in a long-term health care facility. *Am J Cardiol* 1987;59:381-2.
- Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. *Eur Heart J* 1994;15:865-70.
- Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. *Clin Cardiol* 1991;14:995-9.
- Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). *Am J Cardiol* 1995;76:928-32.
- Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. *J Chronic Dis* 1984;37:407-15.
- Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). *Am J Cardiol* 1985;55:744-7.
- Novaro GM, Pearce GL, Sprecher DL, Griffin BP. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting. *J Heart Valve Dis* 2001;10:19-24.
- Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. *J Am Coll Cardiol* 1997;29:630-4.
- Cuniberti LA, Stutzbach PG, Guevara E, Yannarelli GG, Laguens RP, Favalaro RR. Development of mild aortic valve stenosis in a rabbit model of hypertension. *J Am Coll Cardiol* 2006;47:2303-9.
- Yannarelli GG, Pesiney C, Brites F, Canel N, Masnatta L, Scheier L y col. Enzimas antioxidantes y biodisponibilidad de óxido nítrico en un modelo de hipertensión renovascular. *Pren Med Argent* 2006;93:459-64.
- O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). *Arterioscler Thromb Vasc Biol* 2006;26:1721-8.
- Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. *Arterioscler Thromb Vasc Biol* 1999;19:1218-22.
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267-78.
- Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. *J Am Coll Cardiol* 2008;52:1769-81.
- Davignon J. Beneficial cardiovascular pleiotropic effects of statins. *Circulation* 2004;109:III39-43.
- Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005;352:2389-97.
- Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. *J Am Coll Cardiol* 2007;49:554-61.
- Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* 2008;359:1343-56.
- Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. *J Exp Med* 1934;59:347-79.
- Marian AJ, Wu Y, Lim DS, McCluggage M, Youker K, Yu QT, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. *J Clin Invest* 1999;104:1683-92.
- Zoghbi WA, Farmer KL, Soto JG, Nelson JG, Quinones MA. Accurate noninvasive quantification of stenotic aortic valve area by Doppler echocardiography. *Circulation* 1986;73:452-9.
- Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. *N Engl J Med* 2000;343:611-7.
- Mohty D, Pibarot P, Després JP, Côté C, Arsénault B, Cartier A, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. *Arterioscler Thromb Vasc Biol* 2008;28:187-93.
- Pate GE. Association between aortic stenosis and hypertension. *J Heart Valve Dis* 2002;11:612-4.
- Antonini-Canterin F, Huang G, Cervesato E, Faggiano P, Pavan D, Piazza R, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? *Hypertension* 2003;41:1268-72.
- Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. *Hypertension* 1995;25:155-61.
- Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. *Circulation* 2001;103:1933-5.
- Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. *J Invest Med* 2000;48:183-9.
- Gómez-García A, Martínez Torres G, Ortega-Pierres LE,

- Rodríguez-Ayala E, Álvarez-Aguilar C. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. *Rev Esp Cardiol* 2007;60:1242-9.
32. Barenbrock M, Hausberg M, Kosch M, Golubev SA, Kisters K, Rahn KH. Flow-mediated vasodilation and distensibility in relation to intima-media thickness of large arteries in mild essential hypertension. *Am J Hypertens* 1999;12:973-9.
33. Li J, Zhao SP, Li XP, Zhuo QC, Gao M, Lu SK. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. *Int J Cardiol* 1997;61:165-9.
34. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. *Hypertension* 2001;37:1450-7.
35. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Díaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest* 1998;101:2711-9.
36. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. *Hypertension* 1999;34:1281-6.
37. Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? *Curr Opin Nephrol Hypertens* 2003;12:181-7.
38. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation* 1999;100:2131-4.
39. Kang BY, Mehta JL. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. *J Cardiovasc Pharmacol Ther* 2009;14:283-91.

Acknowledgements

The authors are grateful to Laboratorios Gador for having kindly provided the active ingredient rosuvastatin.